证券代码：688690 证券简称：纳微科技 公告编号：2026-010 苏州纳微科技股份有限公司 关于2026年员工持股计划完成股票过户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 苏州纳微科技股份有限公司（以下简称"公司"）于 2026 年 1 月 26 日召开 第三届董事会第十三次会议，并于 2026 年 2 月 12 日召开 2026 年第一次临时股 东会，审议通过《关于公司<2026 年员工持股计划（草案）>及其摘要的议案》《关 于公司<2026 年员工持股计划管理办法>的议案》等相关议案，具体内容详见公 司于 2026 年 1 月 27 日在上海证券交易所网站（www.sse.com.cn）披露的《苏州 纳微科技股份有限公司 2026 年员工持股计划（草案）》及其摘要、《苏州纳微科 技股份有限公司 2026 年员工持股计划管理办法》。 二、本期员工持股计划完成股票过户的情况 根据《关于上市公司实施员工持股计划试点的指导意见》及《上海证券交易 所科创板上市公司自律监管指引第 1 号——规范运作》等法律法规的相 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、持有人会议召开情况 苏州纳微科技股份有限公司（以下简称"公司"）2026 年员工持股计划第 一次持有人会议（以下简称"持有人会议"）于 2026 年 3 月 9 日以现场及通讯 结合的方式召开，本次会议由公司董事会秘书召集和主持，会议应出席持有人 227 人，实际出席会议持有人 189 人，代表公司 2026 年员工持股计划有表决权 的份额为 4,683 万份，占公司 2026 年员工持股计划总份额 6,150 万份的 76.15%。 本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、规 范性文件及《苏州纳微科技股份有限公司 2026 年员工持股计划（草案）》（以 下简称"《2026 年员工持股计划》"）和《苏州纳微科技股份有限公司 2026 年 员工持股计划管理办法》（以下简称"《2026 年员工持股计划管理办法》"） 的规定。 二、持有人会议审议情况 本次会议经审议，通过了如下决议： 证券代码：688690 证券简称：纳微科技 公告编号：2026-009 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [1] Core Insights - The upcoming adjustment of the National Essential Medicines List (NEML) is expected to benefit traditional Chinese medicine (TCM) stocks, with a focus on companies like Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17][22] - The report ranks sub-sectors in the following order of preference: innovative drugs > research services > CXO > TCM > medical devices > pharmacies [2][11] - Historical data indicates that products included in the NEML tend to experience significant sales growth, as seen with Zhaoli Pharmaceutical's Wuling Capsule, which saw sales growth rates increase from -12.82% in 2017 to 32.52% in 2021 after being included in the NEML [19][22] Summary by Sections Investment Highlights - The report suggests focusing on TCM stocks due to the imminent NEML adjustments, recommending Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17] - The report emphasizes the importance of the NEML adjustments, which have not occurred in eight years, and the potential for TCM products to gain market share [22] R&D Progress and Company Dynamics - Recent approvals and submissions include Sanofi's Dupilumab for new indications and GSK's hepatitis B therapy application in Japan [5] - The report highlights various companies across different therapeutic areas, including innovative drugs, ADCs, and small nucleic acids, suggesting a diversified investment approach [13][22] Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 3.0%, with notable performances from specific stocks such as Aidi Te (+36.9%) and Wanze Shares (+27.5%) [10] - The report notes that the medical sector has seen varied performance, with biopharmaceuticals and medical devices showing positive trends, while chemical pharmaceuticals and medical services have faced declines [10]

Financial Performance - The company achieved an operating revenue of 925 million RMB, representing an 18.18% increase compared to the previous year [3] - The comprehensive gross profit margin was 71.31%, an increase of 1.09 percentage points year-on-year [3] - The adjusted net profit attributable to the parent company was approximately 182 million RMB, meeting the budget target for the year [3] Business Strategy - The company implemented a "3+2" market development strategy focusing on three key industries: peptides, bispecific antibodies/ADC, and blood products, while also exploring opportunities in vaccines and small nucleic acids [4] - Sales revenue from core business products, chromatography fillers and media, reached 552 million RMB, a growth of 22.57% year-on-year [4] - International business revenue was approximately 84 million RMB, showing a significant growth of about 78% [4] Research and Development - The company increased its R&D investment to 197 million RMB, an 11.12% increase from the previous year, accounting for 21.29% of the annual operating revenue [5] Profitability Improvement - Operating profit and total profit increased by 88.48% and 87.51% respectively, outpacing the growth rate of operating revenue [7] - The net profit attributable to the parent company grew by 64.18%, while the net profit excluding non-recurring gains and losses increased by 78.55% [7]

Core Viewpoint - Nanwei Technology (688690) reported a significant increase in both revenue and net profit for the year 2025, indicating strong growth and effective international market expansion efforts [1] Financial Performance - The company achieved an operating revenue of 925 million yuan, representing a year-on-year growth of 18.18% [1] - The net profit attributable to shareholders reached 136 million yuan, marking a year-on-year increase of 64.18% [1] International Market Expansion - Nanwei Technology has intensified its efforts in expanding into international markets, enhancing its overseas marketing system, and strengthening sales capabilities [1] - The company reported that its international main business revenue was approximately 84 million yuan, reflecting a year-on-year growth of about 78% [1]

Core Viewpoint - Nanwei Technology (688690.SH) reported a strong performance for the fiscal year 2025, with significant growth in revenue and net profit, indicating a positive outlook for the company [1] Financial Performance - The company achieved an operating revenue of 925 million yuan, representing an 18.18% increase compared to the previous year [1] - The comprehensive gross profit margin was 71.31%, an increase of 1.09 percentage points year-on-year [1] - Adjusted net profit attributable to shareholders was approximately 182 million yuan, meeting the initial budget target for adjusted net profit [1] Net Profit Analysis - The net profit attributable to shareholders reached 136 million yuan, reflecting a substantial growth of 64.18% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 118 million yuan, marking a 78.55% increase compared to the previous year [1] Expense and Loss Provisions - The company recorded share-based payment expenses of 46.2965 million yuan [1] - Provisions for credit and asset impairment losses amounted to 26.7478 million yuan [1]

Core Points - Nanwei Technology announced the receipt of a letter from CITIC Securities regarding the change of the sponsor representative [2] - CITIC Securities is the sponsor for the company's initial public offering (IPO) and listing on the Sci-Tech Innovation Board [2] - The original sponsor representatives were Mr. Zhu Shaohui and Mr. Wang Dong, later changed to Mr. Wang Qi and Mr. Wang Dong in August 2022 [2] - Due to a work adjustment, Mr. Wang Qi will no longer be responsible for the company's ongoing supervision, and Ms. Shao Caijie has been appointed as the new sponsor representative [2] - The legal ongoing supervision period will end on December 31, 2024, and CITIC Securities will continue to oversee the use of the raised funds until they are fully utilized [2] - The change in sponsor representatives does not affect CITIC Securities' ongoing supervision of the company [2]

苏州纳微科技股份有限公司 关于更换保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州纳微科技股份有限公司（以下简称"公司"）于近日收到中信证券股份 有限公司（以下简称"中信证券"）出具的《关于更换保荐代表人的函》，中信 证券作为公司首次公开发行并在科创板上市的保荐机构，原指派的保荐代表人为 朱绍辉先生、王栋先生，并于2022年8月变更为王琦先生、王栋先生，法定持续 督导期截至2024年12月31日，鉴于公司首次公开发行的募集资金尚未使用完毕， 中信证券将对募集资金使用情况继续履行持续督导义务，直至募集资金使用完 毕。 现因王琦先生工作调整，不再负责对公司的持续督导工作，为保证持续督导 工作有序进行，中信证券决定指派邵才捷女士（简历见附件）接替王琦先生担任 公司的保荐代表人，继续履行持续督导职责。本次变更后，公司首次公开发行并 在科创板上市的保荐代表人为邵才捷女士、王栋先生。 证券代码：688690 证券简称：纳微科技 公告编号：2026-008 本次变更不影响中信证券对公司的持续督导工作。公司董事会对王 ...

Core Viewpoint - Nanwei Technology reported a significant increase in both revenue and net profit for the fiscal year 2025, indicating strong business performance and growth potential [2]. Financial Performance - The total operating revenue for the reporting period reached 925 million yuan, representing a year-on-year growth of 18.18% [2]. - The net profit attributable to shareholders of the listed company was 136 million yuan, showing a substantial year-on-year increase of 64.18% [2]. - The basic earnings per share were reported at 0.3394 yuan [2].

Financial Performance - Total operating revenue for 2025 reached RMB 924.69 million, an increase of 18.18% compared to RMB 782.46 million in the previous year[4] - Operating profit rose to RMB 180.12 million, marking an 88.48% increase from RMB 95.56 million year-on-year[4] - Net profit attributable to shareholders was RMB 136.01 million, up 64.18% from RMB 82.84 million in the previous year[4] - The adjusted net profit attributable to shareholders, excluding non-recurring gains and losses, was RMB 117.61 million, reflecting a growth of 78.55% compared to RMB 65.87 million last year[4] - Basic earnings per share increased to RMB 0.3394, up 64.52% from RMB 0.2063 in the previous year[4] Revenue Sources - Sales revenue from core business products, including chromatography fillers and media, reached RMB 552 million, a growth of 22.57% year-on-year[7] - International business revenue was approximately RMB 84 million, showing a significant increase of about 78% compared to the previous year[7] Investment and Assets - Research and development investment amounted to RMB 197 million, an increase of 11.12%, representing 21.29% of total operating revenue[8] - Total assets at the end of the reporting period were RMB 2,415.67 million, a 4.59% increase from RMB 2,309.60 million at the beginning of the period[4] Profitability Metrics - The comprehensive gross profit margin improved to 71.31%, an increase of 1.09 percentage points from the previous year[6]